Drug development can be very complex. In fact, there are currently around 10,223 drug products in development – many of which have a low chance of reaching commercialisation. All development risks must be understood and mitigated as much as possible to increase the likelihood of success. This is especially true if you are an emerging pharma business – the stakes are higher for smaller businesses as they have limited extra capital to mitigate against the impact of project delays. 

To help make sure your business is on the right track, our team of experts at SMoldons Pharmaceuticals UK have devised seven golden rules to help emerging pharmaceutical companies take new drugs quickly and safely to proof of concept.

We explore this in more detail in our eBook for drug development for emerging pharma.